Ultimately, our investigation into JARID1D-mediated signaling within the tumor-bone cell interaction revealed that following JIB-04 treatment, there was upregulation of JARID1D, whereas MAOA and JunD expression were downregulated. Here, JUND is linked to neoplasm.